Glossary

Back

Welcome to the Glossary

Here you will find a list with explanations of the technical terms and abbreviations related to the topic of medical cannabis. With the help of the mouse-over function, you will get a preview of the meaning of underlined words within the page texts. If you click on these, you will be taken to the glossary.

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod

Perspectives in cannabis therapy

Scroll

Introduction

01

Opportunities and perspectives of therapy with medical cannabis

Cannabinoid-based therapy has already been successfully used in various countries - for example Israel and Canada - for a growing number of patients for various clinical pictures. Fette Pharma aims to offer medical cannabis also in Germany for a promising treatment and care of patients as well as in the form of a practice-oriented selection of individually tunable therapy options.

Current basic research on cannabis

02

Current basic research on cannabis and clinical research on the therapeutic use of medical cannabis

Although the use of cannabis as a medicine dates back many centuries, detailed research into the active ingredients of the cannabis plant is even today still in its infancy. Currently, the active properties of the cannabinoids, THC and CBD are being investigated in clinical studies. However, the cannabis plant also contains a large number of active substances such as terpenes, flavonoids and other ingredients: So far, more than 550 substances have been isolated and at least 144 of these are classified as cannabinoids.1,2 The aim of cannabis research is to analyze the plant and its components and to understand its effects in the human organism in order to achieve the greatest possible therapeutic success in the future.

Potential of cannabinoids

03

Promising potential of cannabinoids for the individual therapy of the future

Thanks to ongoing research into new possible combinations of various cannabinoids in coordinated proportions, therapy options may open up for further clinical pictures and symptoms that are not yet the focus of therapy with medical cannabis. The collaboration between Fette Pharma (Germany) and Cannbit (Israel) in cannabis research already shows great potential for finding the right therapy for many patients through research into further combinations of active ingredients.

Optimization of treatment modalities

04

Commitment to a continuous optimization of treatment modalities with scientific support

The close cooperation with experts from Israel (such as the research team led by Prof. Raphael Mechoulam) who have set the milestones in the research of the cannabis plant and the human endocannabinoid system, should also facilitate innovative options in cannabis therapy in Germany.

Thanks to the long-standing research lead of the partner company Cannbit in Israel, Fette Pharma has a large pool of valid clinical study data and scientific findings for the development of its own preparations. This aspect is a decisive contribution to the decoding of further active ingredients of the cannabis plant and is also the foundation for being able to transfer statements and experience from the Israeli study results to our own products.

Find out more about this and other topics in our exclusive area.

To the area for health professionals

References

Status: 2021

  1. Freeman TP et al. Medicinal use of cannabis based products andcannabinoids. BMJ 2019;365:l1141 doi: 10.1136/bmj.l1141 . https://www.bmj.com/content/bmj/365/bmj.l1141.full.pdf (last visited on 08 Feb 22).

  2. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 2011;163:1344–1364.